ASCO 2026 | How will adjuvant cemiplimab improve outcomes in high risk CSCC?
Danny Rischin, MD, Peter MacCallum Cancer Centre, Melbourne, Australia, comments the approval of adjuvant cemiplimab by the FDA and in Europe, making it a standard of care option for high-risk cutaneous squamous cell carcinoma (CSCC), and highlights the promising results of neoadjuvant use of cemiplimab, which are being further tested in phase three trials. These trials will provide more insight into the efficacy of this new treatment paradigm. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So based on the results of the C-POST trial, adjuvant cemiplimab has now been approved by the FDA and in Europe, and it’s really a standard of care option. Other strategies, so it’s a new treatment, a new treatment paradigm. Other strategies such as neoadjuvant use of Cemiplimab have shown promising results, and they’re now being tested in phase three trials, but we’ll need to await the results of those trials...
So based on the results of the C-POST trial, adjuvant cemiplimab has now been approved by the FDA and in Europe, and it’s really a standard of care option. Other strategies, so it’s a new treatment, a new treatment paradigm. Other strategies such as neoadjuvant use of Cemiplimab have shown promising results, and they’re now being tested in phase three trials, but we’ll need to await the results of those trials.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
